Pharmacovigilance in Perspective

[1]  R. Meyboom,et al.  Non-puerperal lactation associated with antidepressant drug use. , 2003, British journal of clinical pharmacology.

[2]  R. Mann,et al.  Prescription-event monitoring--recent progress and future horizons. , 2002, British journal of clinical pharmacology.

[3]  D. McNamee.  Pharmacovigilance into 2000 , 1999, The Lancet.

[4]  R. Meyboom,et al.  Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. , 1999, British journal of clinical pharmacology.

[5]  J. O’Donnell.  Detection of New Adverse Drug Reactions, 4th Edition , 1999 .

[6]  A. Herxheimer.  Secret out-of-court settlements in drug-injury cases , 1999, The Lancet.

[7]  F. Mackay.  Post-Marketing Studies , 1998, Drug safety.

[8]  J. Evans,et al.  Do H2‐receptor antagonists cause acute pancreatitis? , 1998, Pharmacoepidemiology and drug safety.

[9]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[10]  H. Davis.  Use of computerized health claims data to monitor compliance with antibiotic prophylaxis in sickle cell disease , 1998, Pharmacoepidemiology and drug safety.

[11]  T. Lancet.  Time to act to avoid drug-safety scares , 1997, The Lancet.

[12]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[13]  I. Edwards,et al.  The Challenge of Effectively Communicating Risk-Benefit Information , 1997, Drug safety.

[14]  I. Ralph Edwards,et al.  Principles of Signal Detection in Pharmacovigilance , 1997, Drug safety.

[15]  D. McNamee.  Speaking about pharmacovigilance , 1996, The Lancet.

[16]  R. Meyboom,et al.  Characteristics of Topics in Pharmacovigilance in The Netherlands , 1996 .

[17]  G. Macfarlane,et al.  Pharmacoepidemiology (2nd ed) , 1996 .

[18]  R. Meyboom,et al.  Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals , 1996, BMJ.

[19]  Broekmans Aw,et al.  Current regulations for reporting of side effects in The Netherlands after 1995 , 1996 .

[20]  A. Goldberger.  Non-linear dynamics for clinicians: chaos theory, fractals, and complexity at the bedside , 1996, The Lancet.

[21]  I. Edwards,et al.  Impact and Credibility of the Who Adverse Reaction Signals , 1996 .

[22]  M. Lindquist,et al.  Omeprazole and visual disorders: seeing alternatives , 1996, Pharmacoepidemiology and drug safety.

[23]  Patrick van der Smagt,et al.  Introduction to neural networks , 1995, The Lancet.

[24]  J. Fries.  ARAMIS and toxicity measurement. (Arthritis Rheumatism and Aging Medical Information System). , 1995, The Journal of rheumatology.

[25]  B. Inman.  30 years in postmarketing surveillance. A personal perspective , 1993 .

[26]  Leopold Meyler,et al.  Meyler's Side Effects of Drugs , 1992 .

[27]  B. Stricker,et al.  Serum sickness-like reactions to cefaclor. , 1992, Journal of clinical epidemiology.

[28]  R. Mann.  Drug safety alerts — a review of ‘current problems’ , 1992 .

[29]  C. Libersa,et al.  [From antiarrhythmic effects to pro-arrhythmic effects]. , 1992, The´rapie (Paris).

[30]  Meyboom Rh.  Adverse reaction to drugs in children, experiences with "spontaneous monitoring" in The Netherlands. , 1991 .

[31]  M. Lindquist,et al.  Quality criteria for early signals of possible adverse drug reactions , 1990, The Lancet.

[32]  M. Dukes,et al.  Responsibility for Drug - Induced Injury : A Reference Book for Lawyers, the Health Professions and Manufacturers , 1989, The Cambridge Law Journal.

[33]  M D Rawlins,et al.  Spontaneous reporting of adverse drug reactions. I: the data. , 1988, British journal of clinical pharmacology.

[34]  M D Rawlins,et al.  Spontaneous reporting of adverse drug reactions. , 1986, The Quarterly journal of medicine.

[35]  E. Napke,et al.  More on excipients and additives. , 1985, Canadian Medical Association journal.

[36]  G. Venning.  Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms , 1982, British medical journal.

[37]  W. Inman.  Monitoring for drug safety , 1981 .

[38]  R. Meyboom.  New strategies for drug monitoring. , 1977, British medical journal.

[39]  C. Dollery,et al.  Monitoring adverse reactions to drugs. , 1977, British medical journal.

[40]  D. J. Finney,et al.  Statistical Logic in the Monitoring of Reactions to Therapeutic Drugs , 1971, Methods of Information in Medicine.

[41]  J. Evans,et al.  Record-linkage for pharmacovigilance in Scotland. , 1999, British journal of clinical pharmacology.

[42]  Role of causality assessment in pharmacovigilance , 1997 .

[43]  C. Medawar.  Secrecy and medicines. , 1996, The International journal of risk & safety in medicine.

[44]  M. Dukes.  Drug regulation and the tradition of secrecy. , 1996, The International journal of risk & safety in medicine.

[45]  B. Charlton,et al.  Attribution of causation in epidemiology: chain or mosaic? , 1996, Journal of clinical epidemiology.

[46]  A. Herxheimer.  Side effects: freedom of information and the communication of doubt* , 1995 .

[47]  R. Mann.  Databases, privacy, and confidentiality—the effect of proposed new legislation on pharmacoepidemiology and drug safety monitoring* , 1994 .

[48]  T. Gross.  The Analysis of Postmarketing Drug Surveillance Data at the U.S. Food and Drug Administration , 1992 .

[49]  Brian L. Strom,et al.  Drug Epidemiology and Post-Marketing Surveillance , 1992, NATO ASI Series.

[50]  R. Meyboom.  Adverse reaction to drugs in children, experiences with "spontaneous monitoring" in The Netherlands. , 1991, Bratislavske lekarske listy.

[51]  J. Griffin,et al.  Voluntary systems of adverse reaction reporting--Part III. , 1989, Adverse drug reactions and acute poisoning reviews.

[52]  C. E. Lumley,et al.  The under-reporting of adverse drug reactions seen in general practice , 1986 .

[53]  J. Griffin,et al.  Voluntary systems of adverse reaction reporting--Part I. , 1985, Adverse drug reactions and acute poisoning reviews.

[54]  Griffin Jp,et al.  Voluntary systems of adverse reaction reporting--Part III. , 1985 .

[55]  M. D. B. Stephens,et al.  The detection of new adverse drug reactions , 1985 .

[56]  Drug-induced blood dyscrasias in Sweden , 1983 .

[57]  International drug monitoring: the role of national centres. Report of a WHO meeting. , 1972, World Health Organization technical report series.